Physician profile
Nancy P Wiggins
NPI 1821063470
$9,837.28
in general payments reported to CMS, 2019-2025
26 companies · $1,611 in 2025
The $1,611 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $998 · 2020: $536 · 2021: $863 · 2022: $1,843 · 2023: $1,753 · 2024: $2,233 · 2025: $1,611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,595 · Gift: $1.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,595.28 |
| Gift | $1.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $2,167.88 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $1,053.20 | 2019-2025 | Cequa |
| Alcon Vision LLC | $928.38 | 2019-2025 | Tryptyr, Precision7, Hydrus Microstent |
| Allergan, INC. | $767.78 | 2019-2022 | |
| Oyster Point Pharma, INC. | $754.40 | 2022-2024 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $694.29 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $546.63 | 2024-2025 | Xdemvy |
| Abbvie INC. | $426.13 | 2022-2025 | Vuity, Lumigan, Alphagan P |
| Johnson & Johnson Vision Care, INC. | $357.18 | 2022-2024 | Acuvue |
| Biotissue Holdings INC. | $344.66 | 2019-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $308.88 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $207.35 | 2024-2025 | Syfovre |
| Aerie Pharmaceuticals, INC. | $182.75 | 2021 | |
| Kala Pharmaceuticals, INC. | $158.88 | 2021-2022 | |
| Shire North American Group INC | $146.86 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optovue, INC. | $144.74 | 2019 | |
| Thea Pharma INC. | $130.32 | 2022-2025 | Iyuzeh |
| Glaukos Corporation | $112.88 | 2022 | |
| Astellas Pharma US INC | $96.20 | 2024 | Izervay |
| Dompe US, INC. | $95.23 | 2022-2025 | Oxervate |
| Coopervision INC. | $80.67 | 2019-2022 | |
| Eyevance Pharmaceuticals LLC | $48.86 | 2020-2022 | |
| Amgen INC. | $27.09 | 2024 | Tepezza |
| Harrow Eye, LLC | $26.78 | 2024 | Vevye |
| Horizon Therapeutics Plc | $17.60 | 2023 | Tepezza |
| Akorn, INC. | $11.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Wiggins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.